Factors contributing to carboplatin blockade and interruption in its route of administration in paclitaxel-carboplatin therapy

被引:0
|
作者
Inoue, Motoki [1 ]
Nakadate, Kazuhiko [1 ]
Oosaki, Mami [2 ]
Shirota, Mikio [2 ]
Yasu, Takeo [1 ,2 ,3 ,4 ]
机构
[1] Meiji Pharmaceut Univ, Tokyo, Japan
[2] Tokyo Metropolitan Bokutoh Hosp, Dept Pharm, Tokyo, Japan
[3] Meiji Pharmaceut Univ, Bokutoh Hosp, Joint Res Ctr, Tokyo, Japan
[4] Meiji Pharmaceut Univ, Pharmaceut Educ & Res Ctr, Dept Med Therapy Res, 2 522 1 Noshio, Kiyose, Tokyo 2048588, Japan
来源
DRUG DISCOVERIES AND THERAPEUTICS | 2023年 / 17卷 / 03期
关键词
adsorption; catheters; scanning electron microscopy; syringe pushing force;
D O I
10.5582/ddt.2022.01121
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interruption of anticancer infusion processes in patients undergoing chemotherapy may affect their quality of life and the efficacy and safety of the therapy. We experienced several interruptions of carboplatin infusion in multiple patients receiving paclitaxel-carboplatin combination therapy. Therefore, we investigated the causes of these interruptions. The filter and catheter surfaces were evaluated by scanning electron microscopy. Moreover, using a texture analyzer, the mechanical strengths of catheter-attached syringes were compared pre- and post-administration. We observed that the syringe pushing force requirement was higher following dripping failure. However, precipitates were not evident on the filter surfaces, regardless of the dripping failure route. In this case, some of the drug adhered to the catheters' surfaces and interrupted the carboplatin titration. Consequently, in patients receiving combination therapy with paclitaxel and carboplatin, and experiencing interruptions in carboplatin infusion, attention should be paid to the catheter.
引用
收藏
页码:214 / 216
页数:3
相关论文
共 50 条
  • [21] Paclitaxel-carboplatin combination chemotherapy in advanced breast cancerAccumulating evidence for synergy, efficacy, and safety
    G. Pentheroudakis
    E. Razis
    A. Athanassiadis
    N. Pavlidis
    G. Fountzilas
    Medical Oncology, 2006, 23 : 147 - 160
  • [22] Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer:: A phase II study
    Mäenpää, JU
    Grénman, SE
    Jalkanen, JT
    Kuoppala, TA
    Leminen, AO
    Puistola, US
    Vuolo-Merilä, PM
    Yliskoski, MH
    GYNECOLOGIC ONCOLOGY, 2006, 101 (01) : 114 - 119
  • [24] Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage I-II Cervical Cancer
    Salihi, Rawand
    Leunen, Karin
    Moerman, Philippe
    Amant, Frederic
    Neven, Patrick
    Vergote, Ignace
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (06) : 1256 - 1260
  • [25] Gemcitabine-paclitaxel-carboplatin (PCG) versus paclitaxel-carboplatin (PC) in advanced non-small cell lung cancer (NSCLC): Quality of life (QOL) analysis
    Oniga, F.
    Paccagnella, A.
    Luise, A.
    Biason, R.
    Ghi, M. G.
    Gatti, C.
    Nascimben, O.
    Mastromauro, C.
    Medici, M.
    D'Amanzo, P.
    Carnuccio, R.
    McMahon, L.
    ANNALS OF ONCOLOGY, 2006, 17 : XI19 - XI19
  • [26] Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy
    Takemoto, Shuji
    Ushijima, Kimio
    Honda, Kazumi
    Wada, Hiroko
    Terada, Atsumu
    Imaishi, Hiroto
    Kamura, Toshiharu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (04) : 367 - 372
  • [27] Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?
    Jelavic, Tihana Boraska
    Boban, Toni
    Brcic, Luka
    Vrdoljak, Eduard
    ANTI-CANCER DRUGS, 2017, 28 (08) : 922 - 927
  • [28] Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel-carboplatin therapy responded to autologous formalin-fixed tumor vaccine
    Chen, Jui-Tung
    Ohno, Tadao
    CLINICAL CASE REPORTS, 2015, 3 (10): : 823 - 826
  • [29] ANTIEMETIC EFFECTS BY 1-DAY VERSUS 3-DAY DEXAMETHASONE WITH PALONOSETRON FOLLOWING PACLITAXEL-CARBOPLATIN THERAPY
    Watanabe, H.
    Hoshi, I.
    Nakai, Y.
    Yana, T.
    ANNALS OF ONCOLOGY, 2013, 24
  • [30] THE PRESENCE OF M2 MACROPHAGES IN OVARIAN CANCER IS INFLUENCED BY TUMOR STAGE AND GRADE, NOT BY THE ADMINISTRATION OF PACLITAXEL-CARBOPLATIN: A PILOT STUDY
    Baert, T.
    Mathivet, T.
    Van Hoylandt, A.
    Vergote, I.
    Coosemans, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1282 - 1282